Astal Laboratories subsidiary appoints new statutory auditor

Astal Laboratories Limited has disclosed the appointment of a new statutory auditor for its material wholly owned subsidiary, M/s. Sriven Pharmachem India Private Limited. This decision was taken during the board meeting of the subsidiary held on May 19, 2026, to fill the casual vacancy caused by the resignation of M/s. Balaji V & Co.

The board approved the appointment of M/s. Khedar Ankur & Associates Chartered Accountants, bearing Firm Registration Number 040042N. The appointment is effective from May 19, 2026. The firm is a professionally managed proprietorship based in Delhi, led by CA Ankur Khedar.

Auditor Profile

M/s. Khedar Ankur & Associates provides a wide range of professional services. These include statutory audits, internal audits, tax audits, and direct and indirect taxation. The firm also offers GST advisory and compliance, accounting and financial reporting support, certification services, and other regulatory advisory assignments across diverse sectors.

Appointment Details

The following table summarizes the key details regarding the change in statutory auditors:

Particulars	Details
Name of the Firm	M/s. Khedar Ankur & Associates Chartered Accountants
Firm Registration Number	040042N
Reason for change	Appointment of Auditor
Date of appointment	May 19, 2026

The disclosure was made to the stock exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.56%	-7.22%	+15.50%	-16.73%	-11.94%	+745.71%

Astal Laboratories Limited has announced the allotment of 14,70,000 equity shares upon the conversion of warrants by persons belonging to the non-promoter category. The decision was approved by the Board of Directors during a meeting held on May 12, 2026, at the company's corporate office in Telangana.

The equity shares have been issued at a price of ₹40 each, which includes a face value of ₹10 and a premium of ₹30 per share. The company received the remaining 75% of the issue price, totaling ₹4,41,00,000, upon the conversion of these warrants. The warrants were originally allotted on a preferential basis on November 27, 2024.

Allotment Details

The preferential issue was made to 11 strategic investors classified as non-promoters. The allotment was conducted following a special resolution passed by shareholders at the Annual General Meeting held on August 5, 2024, and subsequent in-principle approval from BSE Limited.

Sr. No.	Name of the Allottees	No. of Equity Shares allotted
1.	DORADLA RANGA RAO	60,000
2.	VENKATA KASI ANURADHA YAKKALA	240,000
3.	SANKU DURGA SREE	20,000
4.	PRASUNAMBA KUCHIMANCHI	70,000
5.	RUKMINI PRABHA NAMBURI	50,000
6.	JNV SURESH KUMAR	230,000
7.	SRI HARSHA SOMA	50,000
8.	SOMA SWATI	150,000
9.	E VENKATACHALAM PRASAD	400,000
10.	KOPURI VIJAYA KUMAR GUPTA	100,000
11.	PALETH SHREE KUMAR MENON	100,000

Capital Structure Update

Consequent to this allotment, the paid-up equity capital of astal laboratories has increased. The capital has risen from ₹42,21,56,320, consisting of 42,21,56,320 equity shares of ₹10 each, to ₹43,68,56,320, consisting of 43,68,56,320 equity shares of ₹10 each.